Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,484,021
  • Shares Outstanding, K 161,931
  • Annual Sales, $ 484,150 K
  • Annual Income, $ -167,870 K
  • 60-Month Beta 0.61
  • Price/Sales 5.21
  • Price/Cash Flow N/A
  • Price/Book 5.93
Trade ACAD with:

Options Overview Details

View History
  • Implied Volatility 34.37% ( +12.45%)
  • Historical Volatility 49.09%
  • IV Percentile 2%
  • IV Rank 17.04%
  • IV High 198.03% on 06/06/22
  • IV Low 0.75% on 11/22/22
  • Put/Call Vol Ratio 0.02
  • Today's Volume 55
  • Volume Avg (30-Day) 199
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 15,171
  • Open Int (30-Day) 15,577

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.25
  • Number of Estimates 10
  • High Estimate -0.20
  • Low Estimate -0.30
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +7.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.73 +14.79%
on 11/04/22
16.59 -5.00%
on 11/11/22
-0.17 (-1.07%)
since 11/02/22
3-Month
13.73 +14.79%
on 11/04/22
18.78 -16.08%
on 10/06/22
-0.97 (-5.80%)
since 09/02/22
52-Week
12.24 +28.76%
on 06/21/22
28.06 -43.82%
on 04/07/22
-4.18 (-20.96%)
since 12/02/21

Most Recent Stories

More News
Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ACAD : 15.76 (+2.74%)
BPMC : 48.93 (+3.03%)
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ACADIA Pharmaceuticals...

ACAD : 15.76 (+2.74%)
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD

/PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that...

ACAD : 15.76 (+2.74%)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:

ACAD : 15.76 (+2.74%)
Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss

Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.

AMRN : 1.2200 (+2.52%)
ACAD : 15.76 (+2.74%)
AVIR : 4.80 (+0.42%)
AKRO : 45.46 (-0.50%)
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ACAD : 15.76 (+2.74%)
VTVT : 0.8200 (-5.07%)
Acadia: Q3 Earnings Snapshot

Acadia: Q3 Earnings Snapshot

ACAD : 15.76 (+2.74%)
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022.

ACAD : 15.76 (+2.74%)
Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?

Viatris (VTRS) Q3 results are likely to be impacted by foreign exchange rate fluctuations. An update on the deal with Biocon is also expected along with the results.

JAZZ : 157.25 (+0.45%)
ACAD : 15.76 (+2.74%)
EDIT : 10.25 (+1.89%)
VTRS : 11.17 (-0.62%)
Is a Surprise Coming for Acadia Pharmaceuticals (ACAD) This Earnings Season?

Acadia Pharmaceuticals (ACAD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ACAD : 15.76 (+2.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations...

See More

Key Turning Points

3rd Resistance Point 16.94
2nd Resistance Point 16.43
1st Resistance Point 16.09
Last Price 15.76
1st Support Level 15.24
2nd Support Level 14.73
3rd Support Level 14.39

See More

52-Week High 28.06
Fibonacci 61.8% 22.01
Fibonacci 50% 20.15
Fibonacci 38.2% 18.28
Last Price 15.76
52-Week Low 12.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar